Finance

Lists
Why is BT3 down 7.68%?
Dive Deeper
BT3:FRA
Lineage Cell Therapeutics Inc
€0.80
-7.68%
(-0.067) 1D
Nov 16, 10:00:00 PM GMT+1  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for BT3...
Open
€0.80
High
€0.80
Low
€0.80
Mkt. cap
202.14M
Avg. vol.
137.00
Volume
0.00
52-wk high
€1.68
52-wk low
€0.78
No. of employees
75
Open
€0.80
High
€0.80
Low
€0.80
Mkt. cap
202.14M
Avg. vol.
137.00
Volume
0.00
52-wk high
€1.68
52-wk low
€0.78
No. of employees
75
News stories
From web sources and news partners
Orange County Business Journal
Orange County Business Journal
·
3 days ago
UCI-Founded Company Gets Acquired by Lineage
Profile
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
About Lineage Cell Therapeutics Inc
CEO-
Employees75
Founded1990
Headquarters-
SectorHealth Care
IndustryBiotechnology
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
6.61M
1.72M
1.07M
1.43M
Cost of goods sold
8.30M
4.23M
4.77M
3.82M
Cost of revenue
8.30M
4.23M
4.77M
3.82M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.85M
5.08M
5.22M
4.92M
Operating expense
4.85M
5.08M
5.22M
4.92M
Total operating expenses
13.16M
9.32M
9.99M
8.75M
Operating income
-6.55M
-7.59M
-8.92M
-7.31M
Other non operating income
1.29M
2.32M
9.42M
11.94M
EBT including unusual items
-4.39M
-4.79M
1.54M
4.71M
EBT excluding unusual items
-4.38M
-4.81M
1.54M
4.72M
Income tax expense
-5.28M
-
-
484.00K
Effective tax rate
120.33%
-
-
10.27%
Other operating expenses
-
-
-
-
Net income
851.00K
-4.81M
1.48M
4.23M
Net profit margin
12.88%
-278.96%
138.63%
295.12%
Earnings per share
-
-0.02
0.01
-0.03
Interest and investment income
393.00K
405.00K
378.00K
376.00K
Interest expense
-
-
-
-
Net interest expenses
393.00K
405.00K
378.00K
376.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-6.36M
-7.40M
-8.74M
-7.11M
Gain or loss from assets sale
-
12.00K
19.00K
-
Upcoming events
AI content may include mistakes. Learn more
Google apps